Restless legs syndrome augmentation and pramipexole treatment
Restless legs syndrome augmentation and pramipexole treatment
复制标题
DOI：
10.1016/s1389-9457(02)00144-2
复制
发表时间：
2002-11-01
期刊：
影响因子：
4.8
通讯作者：
Ferini-Strambi, L.
中科院分区：
文献类型：
--
作者：
Ferini-Strambi, L.
目的：对连续60例接受普拉克索(PPX)治疗至少6个月的不宁腿综合征(RLS)患者进行开放式临床系列评估。背景：在RLS患者中，最常见的是长期使用左旋多巴和培高利特。方法：连续60例RLS患者接受PPX治疗至少6个月。结果：5例(8.3%)患者在治疗4-15周后出现强化。继发性RLS的强化发生率(4/21)高于特发性RLS(1/39)。结论：强化与RLS的严重程度或PPX的剂量无关。在大多数RLS患者(66%)中，PPX的最佳治疗剂量(0.25 mg/天)非常低。(C)2002 Elsevier Science B.V.保留所有权利。
Objective: To evaluate in an open-label clinical series the occurrence of restless legs syndrome (RLS) augmentation in 60 consecutive RLS patients treated with pramipexole (PPX) for at least 6 months.Background: In patients with restless legs syndrome (RLS), augmentation is most commonly seen with long-term use of levodopa and pergolide.Method: Open-label clinical series in 60 consecutive RLS patients treated with PPX for at least 6 months.Results: Augmentation was observed in five patients (8.3%) after 4-15 weeks of treatment. Augmentation occurred more frequently in patients with secondary RLS (4/21) than in those with idiopathic RLS (1/39).Conclusions: Augmentation is unrelated to either severity of RLS or doses of PPX. There is a very low optimal therapeutic dose of PPX (0.25 mg/day) in most RLS patients (66%). (C) 2002 Elsevier Science B.V. All rights reserved.